Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

27 Sep 2005 12:09

Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2005 Chairman's statementIn the six months ended 30 June 2005 the Company incurred a loss before andafter taxation of ‚£74,000 (2004: ‚£229,000).Because of the lack of cash in the Company, creditors have increased butcontinue to be supportive.The directors are continuing to keep overheads to a minimum, the expenses beingthose necessary to maintain the Company's listing on AIM.The board continues to seek an acquisition for the Company.Owing to a technicality, the Company no longer has any authority to issue anyof its share capital and will therefore be convening an extraordinary generalmeeting for this purpose.Nicolas GreenstoneChairman27 September 2005Azure Holdings plcProfit and Loss Accountfor the six months ended 30 June 2005 6 months 6 months Year ended ended 30 ended 30 31 December June 2004 2004 June 2005 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000 Turnover - - - Administrative expenses (74) (229) (345) Operating loss (74) (229) (345) Loss on ordinary activities before (74) (229) (345)taxation Tax on loss on ordinary activities - - - Loss on ordinary activities after (74) (229) (345)taxation Retained loss for the period (74) (229) (345) Loss per ordinary share (0.15p) (0.65p) (0.86p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains andlosses.Azure Holdings plcBalance Sheetas at 30 June 2005 30 June 2005 30 June 31 December 2004 2004 (unaudited) (unaudited) (audited) ‚£'000 ‚£'000 ‚£'000 Current assets Debtors 3 14 7 Cash at bank and in hand 1 10 14 4 24 21 Creditors: amounts falling due within one (147) (81) (90)year Net current liabilities (143) (57) (69) Total assets less current liabilities (143) (57) (69) Net liabilities (143) (57) (69) Capital and reserves Called up Share Capital 5,475 5,371 5,475 Share Premium 10,279 10,279 10,279 Profit and loss account (15,897) (15,707) (15,823) Equity shareholders deficit (143) (57) (69) Azure Holdings plcCash Flow Statementfor the six months ended 30 June 2005 6 months ended 6 months ended 30 June 2005 30 June 2004 (unaudited) (unaudited) ‚£'000 ‚£'000 Net cash outflow from operating (13) (214)activities Financing Issue of ordinary shares - 105 Decrease in cash (13) (109)Azure Holdings plcNotes to the Interim Results 1. The interim results are unaudited and do not constitute statutory accounts within the meaning of section 240 of the Companies Act 1985. The figures for the year ended 31 December 2004 have been extracted from the statutory accounts filed with the registrar of companies on which the auditors gave an unqualified report. 2. The interim results have been prepared using the accounting policies set out in the statutory accounts for the year ended 31 December 2004. 3. The comparative figures for the unaudited interim results for the period ended 30 June 2004 are stated as announced on 29 September 2004. 4. Loss per share The earnings per share for the six months ended 30 June 2005 has beencalculated on the basis of the loss after taxation for the period of ‚£74,000(2004: ‚£229,000 ) and the weighted average number of shares in issue during theperiod of 48,317,569 (2004: 35,417,565). 5. The directors do not propose to pay a dividend for the period. 6. Copies of the interim results are available from the Company's registered office, One Great Cumberland Place, London, W1H 7AL. ENDAZURE HOLDINGS PLC
Date   Source Headline
25th Jun 20192:50 pmRNSFurther re: Termination of Subscription Agreement
24th Jun 201912:45 pmRNSHolding(s) in Company
21st Jun 201912:00 pmRNSHolding(s) in Company
20th Jun 20197:00 amRNSUpdate on VAL201 Clinical Trial
19th Jun 201912:00 pmRNSHolding(s) in Company
13th Jun 20197:00 amRNSPlacing, Subscription Agreement & Issue of Warrant
10th Jun 20197:00 amRNSSubscription Agreement Update
5th Jun 20197:00 amRNSNotice of AGM & Update of Subscription Agreement
31st May 201911:07 amRNSSubscription Agreement Update
31st May 201910:42 amRNSHolding(s) in Company
30th May 201910:30 amRNSHolding(s) in Company
29th May 201911:44 amRNSHolding(s) in Company
29th May 20197:00 amRNSFinal Results
28th May 20197:00 amRNSSubscription Agreement Update
23rd May 201912:02 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription Agreement Update
13th May 20192:00 pmRNSPrice Monitoring Extension
2nd May 20197:00 amRNSAcquisition of Intellectual Property& JV Agreement
29th Apr 20192:06 pmRNSSecond Price Monitoring Extn
29th Apr 20192:01 pmRNSPrice Monitoring Extension
29th Apr 201911:07 amRNSSecond Price Monitoring Extn
29th Apr 201911:01 amRNSPrice Monitoring Extension
29th Apr 201910:55 amRNSHolding(s) in Company
26th Apr 20197:00 amRNSSubscription, Convertible Funds and Warrant Issue
15th Apr 20197:15 amEQSHardman & Co Research: Valirx (VAL): VAL401 is going forward
26th Mar 20197:00 amRNSValiSeek Update
21st Mar 20197:00 amRNSUpdate on VAL201 & VAL301 Development Progress
21st Feb 201911:22 amRNSPlacing, Issue of Equity and Warrant
31st Jan 20197:00 amRNSNew patent grant allowances for VAL301
11th Jan 20197:00 amRNSPublication of VAL401 peer-reviewed article
9th Jan 201910:41 amRNSValiRx endorses the Government's new NHS strategy
3rd Jan 20197:00 amRNSHolding(s) in Company
18th Dec 20184:41 pmRNSSecond Price Monitoring Extn
18th Dec 20184:36 pmRNSPrice Monitoring Extension
18th Dec 201811:25 amRNSIssue of Equity / PDMR Shareholdings
18th Dec 20187:00 amRNSUpdate on VAL401 - Peer-review Acceptance
10th Dec 20187:00 amRNSUpdate on VAL201 Clinical Trial
5th Nov 20187:00 amRNSRe scientific and investor meetings
1st Nov 20187:15 amEQSHardman & Co Research: ValiRx (VAL): VAL401 Phase II trial completed
24th Oct 20187:00 amRNSAlign Research Initiates Coverage
17th Oct 20187:00 amRNSVAL201 in concluding stages of Phase I/II trial
15th Oct 201812:00 pmRNSVAL401 results shortly to be on ClinicalTrials.gov
25th Sep 20187:00 amRNSHalf-year Report
14th Sep 201812:42 pmRNSIssue of Equity
6th Sep 20187:00 amRNSUpdate on Clinical Development
24th Jul 201812:17 pmRNSResult of General Meeting
17th Jul 20187:00 amRNSUS PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
6th Jul 20184:42 pmRNSNotice of GM
14th Jun 20187:00 amRNSVAL401 Update
24th May 20189:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.